We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock

Delisted

ISEE was delisted on the 10th of July, 2023.

77 hedge funds and large institutions have $56.3M invested in IVERIC bio, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 34 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

867% more call options, than puts

Call options by funds: $1.31M | Put options by funds: $136K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

23% less funds holding

Funds holding: 10077 (-23)

42% less capital invested

Capital invested by funds: $96.5M → $56.3M (-$40.2M)

56% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 34

63% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 35

Holders
77
Holders Change
-23
Holders Change %
-23%
% of All Funds
1.92%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
15
Reduced
34
Closed
35
Calls
$1.31M
Puts
$136K
Net Calls
+$1.18M
Net Calls Change
+$767K
Name Holding Trade Value Shares
Change
Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$9.15M +$163K +59,700 +2%
AC
2
Armistice Capital
New York
$6.14M +$6.54M +2,400,000 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$5.85M -$1.44M -528,670 -19%
D.E. Shaw & Co
4
D.E. Shaw & Co
New York
$5.62M +$2.56M +939,945 +75%
Renaissance Technologies
5
Renaissance Technologies
New York
$4.27M -$521K -191,200 -10%
BlackRock
6
BlackRock
New York
$2.77M -$3.84M -1,408,919 -57%
Deutsche Bank
7
Deutsche Bank
Germany
$2.48M +$43.6K +16,000 +2%
Millennium Management
8
Millennium Management
New York
$1.96M -$310K -113,649 -13%
BIM
9
Bogle Investment Management
Massachusetts
$1.82M -$1.09M -399,677 -36%
Goldman Sachs
10
Goldman Sachs
New York
$1.67M +$254K +93,349 +17%
TA
11
Tamarack Advisers
California
$1.6M +$419K +153,851 +33%
NI
12
Numeric Investors
Massachusetts
$1.56M -$1.73M -634,518 -51%
QIM
13
Quantitative Investment Management
Virginia
$1.44M -$2.72K -1,000 -0.2%
Connor, Clark & Lunn Investment Management (CC&L)
14
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.33M +$486K +178,575 +52%
OAM
15
Oxford Asset Management
United Kingdom
$788K -$156K -57,163 -16%
Canada Pension Plan Investment Board
16
Canada Pension Plan Investment Board
Ontario, Canada
$667K +$351K +128,900 +98%
PAM
17
Panagora Asset Management
Massachusetts
$619K +$658K +241,674 New
Two Sigma Advisers
18
Two Sigma Advisers
New York
$503K -$719K -263,856 -57%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$477K -$147K -54,018 -22%
ARTA
20
A.R.T. Advisors
New York
$440K -$547K -200,912 -54%
ECM
21
Element Capital Management
New York
$410K +$437K +160,334 New
Point72 Asset Management
22
Point72 Asset Management
Connecticut
$384K +$409K +150,000 New
Morgan Stanley
23
Morgan Stanley
New York
$373K -$5.68M -2,084,004 -93%
PP
24
Paloma Partners
Connecticut
$287K +$306K +112,300 New
Jane Street
25
Jane Street
New York
$284K +$302K +110,963 New

ISEE Hedge Fund Activity: Q2 2017 in Review

77 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q2 2017, worth a combined $56.3M — down 42% from $96.5M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of ISEE and 13 opened new positions — a net loss of 22 holders — while 34 trimmed existing stakes and 15 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $6.54M. The largest seller was Morgan Stanley, cutting an estimated $5.68M.

  • 77 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q2 2017, down from 100 in Q1 2017.
  • Funds reported $56.3M of IVERIC bio, Inc. Common Stock stock for Q2 2017, down 42% quarter-over-quarter.
  • 13 funds opened new IVERIC bio, Inc. Common Stock positions in Q2 2017 and 35 closed out, a net change of -22 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q2 2017 was Armistice Capital, an estimated $6.54M added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q2 2017 was Morgan Stanley, an estimated $5.68M sold.

Based on aggregated 13F filings for Q2 2017.